Viktor Grunwald

Essen, NW 45147, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 175 publications

Impact of COPD on Outcomes After Pulmonary Metastasectomy: A Propensity-Score Matched Analysis.

Impact of COPD on Outcomes After Pulmonary Metastasectomy: A Propensity-Score Matched Analysis.

Journal: Cancers

Published: June 29, 2026

Fumarate hydratase-deficient renal cell carcinoma - results of the exploratory analysis in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line treatment.

Fumarate hydratase-deficient renal cell carcinoma - results of the exploratory analysis in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line treatment.

Journal: Cancer treatment and research communications

Published: May 03, 2026

Real-World Data on the Use of Nivolumab Monotherapy in the Treatment of Advanced Renal Cell Carcinoma After Prior Therapy: Final Results from the Non-Interventional NORA Study.

Real-World Data on the Use of Nivolumab Monotherapy in the Treatment of Advanced Renal Cell Carcinoma After Prior Therapy: Final Results from the Non-Interventional NORA Study.

Journal: Cancers

Published: April 30, 2026

Histotype-specific incidence and survival of urothelial carcinoma-an analysis of the German North Rhine-Westphalia Cancer Registry.

Histotype-specific incidence and survival of urothelial carcinoma-an analysis of the German North Rhine-Westphalia Cancer Registry.

Journal: ESMO real world data and digital oncology

Published: April 03, 2026

MyCODE: a prospective evaluation of lay-language molecular tumor board protocols in precision oncology.

MyCODE: a prospective evaluation of lay-language molecular tumor board protocols in precision oncology.

Journal: The oncologist

Published: February 28, 2026

Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review.

Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 21, 2026

Effectiveness and safety of enfortumab vedotin and pembrolizumab in a real-world patient population with urothelial carcinoma: results from a multi-institutional cohort (GUARDIANS).

Effectiveness and safety of enfortumab vedotin and pembrolizumab in a real-world patient population with urothelial carcinoma: results from a multi-institutional cohort (GUARDIANS).

Journal: Cancer immunology, immunotherapy : CII

Published: February 16, 2026

Clinical characteristics, treatment patterns, and survival outcomes in ductal prostate cancer: a multicenter retrospective analysis.

Clinical characteristics, treatment patterns, and survival outcomes in ductal prostate cancer: a multicenter retrospective analysis.

Journal: World journal of urology

Published: February 12, 2026

NECTIN4 Amplification Is a Frequent Event in Central Nervous System Metastases of Urothelial Carcinoma.

NECTIN4 Amplification Is a Frequent Event in Central Nervous System Metastases of Urothelial Carcinoma.

Journal: European urology open science

Published: February 11, 2026

Effectiveness, toxicity and treatment adjustments of lenvatinib plus pembrolizumab in advanced renal cell carcinoma: a multicenter real-world analysis.

Effectiveness, toxicity and treatment adjustments of lenvatinib plus pembrolizumab in advanced renal cell carcinoma: a multicenter real-world analysis.

Journal: ESMO real world data and digital oncology

Published: February 06, 2026

Molecular subtype concordance and metastatic patterns in muscle-invasive bladder cancer.

Molecular subtype concordance and metastatic patterns in muscle-invasive bladder cancer.

Journal: The journal of pathology. Clinical research

Published: January 08, 2026

Clinical Impact of Immune Checkpoint Inhibitors and Chemotherapy in the First-Line Treatment of Metastatic Urothelial Carcinoma with Variant Histology.

Clinical Impact of Immune Checkpoint Inhibitors and Chemotherapy in the First-Line Treatment of Metastatic Urothelial Carcinoma with Variant Histology.

Journal: Urologia internationalis

Published: December 09, 2025

Showing 1-12 of 175

Last Updated: 09/26/2026